TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours ; volume:122 ; number:5 ; day:20 ; month:12 ; year:2019 ; pages:658-667 ; date:3.2020
British journal of cancer ; 122, Heft 5 (20.12.2019), 658-667, 3.2020
- Creator
-
Saito, Yurina
Takahashi, Tsuyoshi
Obata, Yuuki
Nishida, Toshirou
Ohkubo, Shuichi
Nakagawa, Fumio
Serada, Satoshi
Fujimoto, Minoru
Ohkawara, Tomoharu
Nishigaki, Takahiko
Sugase, Takahito
Koh, Masahiro
Ishida, Tomo
Tanaka, Koji
Miyazaki, Yasuhiro
Makino, Tomoki
Kurokawa, Yukinori
Nakajima, Kiyokazu
Yamasaki, Makoto
Hirota, Seiichi
Naka, Tetsuji
Mori, Masaki
Doki, Yuichiro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-019-0688-y
- URN
-
urn:nbn:de:101:1-2021012517471577425706
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Saito, Yurina
- Takahashi, Tsuyoshi
- Obata, Yuuki
- Nishida, Toshirou
- Ohkubo, Shuichi
- Nakagawa, Fumio
- Serada, Satoshi
- Fujimoto, Minoru
- Ohkawara, Tomoharu
- Nishigaki, Takahiko
- Sugase, Takahito
- Koh, Masahiro
- Ishida, Tomo
- Tanaka, Koji
- Miyazaki, Yasuhiro
- Makino, Tomoki
- Kurokawa, Yukinori
- Nakajima, Kiyokazu
- Yamasaki, Makoto
- Hirota, Seiichi
- Naka, Tetsuji
- Mori, Masaki
- Doki, Yuichiro
- SpringerLink (Online service)
Other Objects (12)
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Einfluss von Imatinib und Rituximab auf immunkompetente Zellen
A Rare Adverse Drug Reaction of Imatinib Mesylate
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Einfluss von Imatinib und Rituximab auf immunkompetente Zellen
A Rare Adverse Drug Reaction of Imatinib Mesylate
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Einfluss von Imatinib und Rituximab auf immunkompetente Zellen